Navigation Links
Galmed Pharmaceuticals Reports First Half 2014 Financial Results

TEL AVIV, Israel, July 25, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (Galmed), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

First Half 2014 Financial Summary:

  • Reported cash and cash equivalents totaling $37.4 million on June 30, 2014, compared with $137,000 at December 31, 2013. 
  • Reported a net loss of $3.9 million for the six months ended June 30, 2014, compared with a net loss of $1.6 million for the comparable prior year period.
  • Reported research and development expenses of $2.7 million for the six months ended June 30, 2014, compared with $1.3 million for the comparable prior year period, primarily resulting from increases in R&D subcontractor expenses and an increase in salaries and benefits due to an increase in clinical staff.
  • Reported general and administrative expenses of $1.1 million for the six months ended June 30, 2014, compared with $247,000 for the comparable prior year period, resulting from an increase in professional services and an increase in salaries and benefits, consisting of non-cash stock-based compensation and an increase in the administrative staff.
  • Reported a net loss per share of $0.42 for the six months ended June 30, 2014, compared with $0.31 per share for the comparable prior year period, in each case not taking into consideration dilution resulting from net loss during both periods.
  • Select Second Quarter 2014 and Recent Corporate Highlights:

  • Received U.S. Food and Drug Administration (FDA), clearance of the Company's Investigational New Drug application for aramchol for the treatment of fatty liver disorders, thereby permitting Galmed to conduct clinical studies for the targeted indication and additional proof of concept studies in the United States in the future.
  • Filed a Fast Track Designation request with the FDA.
  • Published the results of Galmed's Phase IIa trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal.
  • Commenced on schedule, pharmacokinetic and food effect studies in 66 subjects for the higher doses of aramchol that the Company anticipates using in its Phase IIb trial of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH, patients who are also overweight and diabetic.
  • Filed a provisional patent application in the United States for aramchol to treat lipodystrophy, a medical condition characterized by abnormal or degenerative conditions of adipose tissue, or body fat, including the loss of body fat from various regions of the body and its redistribution and accumulation in other areas and for which there is no currently approved medical treatment, based on Galmed's Phase IIa clinical trial of aramchol in 60 non-alcoholic fatty liver disease, or NAFLD, patients, in which a significant reduction in liver fat and improvement of certain metabolic parameters were observed.
  • Independent publication of the importance of the regulation of ABCA1-induced reverse cholesterol transport on the pathogenesis of NASH, which may further support Galmed's belief that aramchol can play a significant role in the pathogenesis of NASH based on Galmed's studies showing the affect of aramchol in increasing ABCA1 activity in in vitro models of human cells by between 300% and 400%.
  • "I am pleased to report that we have completed all short-term milestones that we set for the first half of 2014 at the time of our initial public offering," stated Allen Baharaff, Galmed's Chief Executive Officer. "We are also moving ahead with trial preparation for the Phase IIb NASH trial of aramchol, including the initiation of and patient screening for such trial, as planned. We expect to report interim data by the third quarter of 2015 and top line data by the fourth quarter of 2016. We also expect to initiate a proof of concept study of aramchol for the dissolution and prevention of cholesterol gallstones in the current quarter and anticipate top-line results from this study before year end."

    "In March, we completed an initial public offering of our ordinary shares, which generated net proceeds after deducting underwriting discounts, commissions and expenses of approximately $39.7 million," continued Mr. Baharaff.  "Based on our expected level of expenditures, including all clinical studies and research and development activities we believe necessary for the completion of our planned Phase IIb trial of aramchol in NASH patients, we expect our cash on hand to be sufficient to fund operations through mid 2017, subject, of course, to changes in our burn rate or plans in the future."

    Conference Call Details
    Galmed will host a conference call and webcast today at 8:30 a.m. EDT/5:30 a.m. PDT to discuss its financial results and to provide an update on current developments with respect to its clinical program for aramchol.

    Conference Call & Webcast
    Today, 8:30am EDT/5:30am PDT

    Replay available until August 9:

    About Galmed Pharmaceuticals Ltd.
    Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

    Forward-Looking Statements
    This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.

     GALMED PHARMACEUTICALS LTD.Condensed Consolidated Balance SheetsU.S. Dollars in thousands, except share data and per share dataSuccessorPredecessorAs of
    June 30, 2014As of
    December 31,
    2013UnauditedAuditedAssetsCurrent AssetsCash and cash equivalents$

    Other accounts receivable61

    16Total current assets37,640

    153Property and equipment, net24

    13Total assets$

    Liabilities and Stockholders' DeficiencyCurrent liabilitiesTrade payables$

    Other accounts payable393

    334Total current liabilities694

    1,689Long-term liabilities Related parties442

    428Total long-term liabilities442

    428Stockholders' equity (deficiency):Ordinary shares par value NIS 0.01 per share; 
    Authorized 50,000,000; Issued and outstanding:
    11,100,453 shares as of June 30, 201432

    -Ordinary shares par value $1 per share; Authorized 50,000
    shares; Issued and outstanding: 9,739 shares as of
    December 31, 2013-

    10Additional paid-in capital67,876

    25,681Accumulated deficit (31,560)

    (27,642)Total stockholders' equity (deficiency)36,348

    (1,951)Total liabilities and stockholders' equity$

    The noted included in the 6-K are an integral part of the condensed interim consolidated financial statements. GALMED PHARMACEUTICALS LTD.Condensed Consolidated Statements of OperationsU.S. Dollars in thousands, except share data and per share dataSuccessorPredecessor 

    Period from February 3 to June 30, 2014Period from
    January 1 to
    February 2, 2014Six months
    endedJune 30, 2013UnauditedUnauditedUnauditedResearch and development expenses


    General and administrative expenses


    114247Capital  loss


    -10Total operating expenses3,283

    6151,551Financial expenses, net


    99Net loss$

    Basic and diluted net loss per share


    Weighted average number of shares outstanding used in
    computing basic and diluted net loss per share

    10,073,817(*)  7,099,731(*) 4,995,837(*) Retroactively adjusted to reflect the 729:1 share split, which occurred upon the consummation of the Reorganization.

    SOURCE Galmed Pharmaceuticals Ltd.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
    Post Your Comments:
    (Date:11/24/2015)... -- SHPG ) announced today that Jeff Poulton ... th Annual Healthcare Conference in New York City ... EST (1:30 p.m. GMT). --> SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
    (Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
    (Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
    (Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
    Breaking Biology Technology:
    (Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
    (Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
    (Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
    Breaking Biology News(10 mins):